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Gastric cancer (GC) still represents the second cause of cancer-related death worldwide. Radical resection is the mainstay of early
stages treatment with little impact on overall survival (OS) in the advanced ones. HER-2 is the most relevant biological factor
involved. Purpose. This study aims to show the relationship between HER-2 positivity and survival in patients with completely
resected GC. Methods. Retrospective study of GC patients diagnosed in 2003–2005 at our institution. Surgical specimens
underwent immunohistochemistry (IHC), and in cases +/++/+++ samples underwent also ﬂuorescence in situ hybridisation
(FISH) analyses of HER-2 and graduated according to experts’ consensus. Results. 120 cases included. Overall expression detected
in7.5%.Correlationbetween HER-2positiveandfemalesex, advancedstagesorhistologicalgrades,orintestinaltypewasdetected.
Earlyrecurrences higherinHER-2 positive(66.6%versus35.4%,P = 0.048).ThemedianDFS forc-erbB-2positivewas15months
(range 2–67 months), and OS was 25 months (range 10–67 months). In the case of patients with c-erbB-2, negative median DFS
was 27 months (range 5–67 months) and OS for this sample is 47 months (range 29–67 months). Conclusions. These results
emphasize the relevance of HER-2 positivity in GC as independent prognostic factor and support its current analyses in daily
practice.
1.Introduction
Despite the overall incidence of gastric cancer (GC) has de-
clined in recent decades, it still represents the second cause
of cancer-related death worldwide [1]. There is a wide geo-
graphicalvariationinbothpatternsofincidenceand survival
rates [2]. The highest rates of survival have been recorded
in Japan, where its high incidence has led to implement
screening measures amongthepopulationathigh risk.These
measures have achieved higher rates of earlier detection with
an excellent prognosis [3–5].
Spainrecords a survival rate above the European average,
with 23%of patientsalive at 5 years, except inone of itsareas
with higher incidence rates (Castilla and Le´ on) where it has
been registered the highest mortality [6].
Nowadays, the radical resection is still the mainstay of
treatment and despite the progress made in surgical tech-
niques and development of new therapeutic strategies with
chemotherapy or perioperative chemoradiotherapy, there
have not been a signiﬁcant improvement in the overall sur-
vival (OS) [3, 7].
In the recent years, there has been a change in the pat-
tern of presentation of GC [7], with a relative increase in
the incidence of proximal tumors. Despite diﬀerences in
their biological behavior with a more aggressive clinical
course than distal tumours, little progress has been made in
theknowledge ofnewprognostic factors. Thus, TNM stageis
still the most relevant prognostic factor. Therefore, there is a
wide heterogeneity among individuals with the same tumor
stage. At this time, it would be necessary to have additional
classiﬁcationparametersorbiomarkerstoidentifysubgroups
of patients with diﬀerent biological proﬁles that correlate
more closely with a prognosis and/or response to treatment
[8].
In this context, a better understanding of the biological
basis of GC would be helpful. Recently, many biological fac-
torsinvolvedin thegenesisofsporadicGC havebeenknown,
although their clinical relevance has not been conﬁrmed2 Journal of Oncology
for most of them [9]. HER-2 protein is a transmembrane
tyrosine kinase receptor and a member of the epidermal
growth factor receptors (EGFRs) family [8]. The family
comprisesfourmembers(HER -1toHER -4).AllexceptHER -
3 share the same molecular structure with an extracellular
domain of ligand binding, a short transmembrane domain,
and an intracellular domain with tyrosine kinase activity.
HER-3 is a distinctive member of this family because its
kinase domain lacks certain residues that are known to be
essential for catalytic activity in other kinases [10].
Ligand bindingtoitsreceptortriggersacascadeofsignals
thatinﬂuencemany aspectsoftumorbiologyasimportant as
cell diﬀerentiation, proliferation, and cell survival [11, 12].
HER-2 protein is encoded by a gene located on chromo-
some 17q21 that acts as oncogene in carcinomas because its
overexpression induces ampliﬁcation of the protein in the
cell membrane, and consequently the malignant cell gets fa-
vorable for their growth properties.
The role of HER-2 in the development of many types of
cancer is well known, especially in invasive breast cancer in
which overexpression of the protein in the cell membrane
and/or gene ampliﬁcation has been detected in 10–34%,
correlating with worse prognosis and being a predictor of
poor response to chemotherapy and hormonal treatments
[8]. Although this overexpression has also been detected
in other tumors, including GC, its prognostic impact has
not been deﬁnitively established [13, 14]. The interest in
this biological factor has been increased by the presence
of trastuzumab, a humanized IgG1 monoclonal antibody
that speciﬁcally binds the extracellular domain of HER-2
and increases survival rates in breast tumors early and at
advanced stage [8]. These results encourage to investigate
the prognostic signiﬁcance of HER-2 protein in other types
of tumors with high incidence and few therapeutic options,
such as GC. Overexpression of HER-2 in this disease was
ﬁrst described in 1986 by immunohistochemistry (IHC) [8].
Several published series have shown positivity rates varying
between 6.8% and 34% for IHC and 7.1% to 42.6% for the
ampliﬁcation of gene copy number by ﬂuorescence in situ
hybridization or FISH [15–17].
They have also shown higher positivity rates in intestinal
type tumors and proximal location (gastroesophageal junc-
tion) [8].
On the other hand, Funato et al., using GC cell lines that
overexpress HER-2, found that this conferred sensitivity to
cisplatin, suggesting that positivity could be a predictor of
response to this drug [18].
Although several studies have attempted to demonstrate
its prognostic role, this has not been deﬁnitively proven [13,
14]. Some studies have suggested that overexpression and/or
ampliﬁcation in GC after radical resection would be an in-
dependent prognostic factor related to the depth of gastric
wall invasion, lymph node involvement, undiﬀerentiated
tumours,andreduceddisease-free survival (DFS)orOS[15–
17, 19].
This study tries to demonstrate the relationship between
HER-2 positivity and survival in a speciﬁc population of pa-
tients living in an area of high risk of GC in the center of
Spain who underwent a complete resection.
2.Materialand Methods
2.1. Study Design and Eligible Population. This was designed
as a retrospective study of patients diagnosed with GC in the
period from 2003 to 2005 which were analysed histopatho-
logically at the Department of Pathology of the Clinical
University Hospital of Valladolid (Castilla and Le´ on, Spain).
Men and women older than 18 years of age were eligible
for inclusion if they had histologically conﬁrmed adeno-
carcinoma of the stomach or gastrooesophageal junction.
All of them had to be undergone a complete radical resec-
tion R0 and followed our institutional standard followup.
Major exclusion criteria included induction chemotherapy
or metastases at diagnosis.
2.2. Pathological Study. The analyses were performed in
tissue sections of 3 mm tissue blocks conventionally ﬁxed
in formalin and embedded in paraﬃn. These samples were
subjected to analysis of overexpression by IHC, and in cases
with +/++/+++ these samples underwent also an analysis of
HER-2 ampliﬁcation using the techniques described below.
Tumours were tested for HER-2 status with IHC through
HercepTest kit (DAKO K5207 manual process number of
the sample) according to manufacturer protocols. For the
assessment byIHC,we usedthemembrane stain graduations
on a scale of 4 grades: 0, 1+, 2+, 3+ according to the recom-
mendations of the panel scoring GC [20]( s e eTable 1).
We performed also FISH. For this procedure, we used
the DAKO kit pharmDx. The rate of HER-2 ampliﬁcation
was determined by the ratio between the number of copies
of HER-2/number of centromeres (ratio of HER-2/CEP 17
(centromeric probe 17)). A rate of ≥2 was considered posi-
tive,indicatinggeneampliﬁcation.Polysomyofchromosome
17 was deﬁned as ≥3 CEP 17 signals per cell on average.
The analysis was carried outbytwo experienced patholo-
gists independently. If no consistent assessment, the case was
analyzed by both of them, and the result was obtained by
consensus.
This technique was used in conjunction with IHC rou-
tinely in all patients with at least +IHCto assess concordance
as it has been explained above.
2.3. Endpoints. The primary endpoints were DFS and OS.
DFS was deﬁned as time from radical surgery until recur-
rence, death of any cause other than cancer, or last followup.
OS was considered of radical resection until death from any
cause.
Secondary endpoints included frequency of overexpres-
sion and/or ampliﬁcation in GC, time to progression, and
correlation between the status of the overexpression and/or
ampliﬁcation with other pathological, anatomic, or relevant
demographic features.
2.4. Study Variables. We reviewed the medical records of
each case and collected the clinical, demographic and patho-
logical data.
Demographic data were area of origin of patients, age,
and sex.Journal of Oncology 3
Table 1: Immunohistochemistry scoring for HER2 in gastric and gastrooesophageal junction cancer, by type of diagnostic specimen.
IHC Surgical specimen Biopsy specimen HER2 overexpression interpretation
0 No reactivity or membranous reactivity
in <10% of tumour cells
No reactivity or no membranous
reactivity in any tumour cell Negative
+
Faint or barely perceptible membranous
reactivity in ≥10% of tumour cells; cells
are reactive only in part of their
membrane
Tumour cell cluster with a faint or barely
perceptible membranous reactivity
irrespective of percentage of tumour cells
stained
Negative
++
Weak to moderate complete, basolateral,
or lateral membranous reactivity in
≥10% of tumour cells
Tumour cell cluster with a weak to
moderate complete, basolateral,or lateral
membranous reactivity irrespective of
percentage of tumour cells stained
Equivocal
+++
Strong complete, basolateral, or lateral
membranous reactivity in ≥10% of
tumour cells
Tumour cell cluster with a strong
complete, basolateral, or lateral
membranous reactivity irrespective of
percentage of tumour cells stained
Positive
Clinical and pathological data are, for example, tumor
location, endoscopic appearance, histologic type of Lauren,
endoscopic diagnosis date, date of radical resection, TNM
pathologic stage, ratio of metastatic nodes/analyzed nodes,
adjuvant treatment, date of recurrence, location of recur-
rence, relapse type (single/multiple), date of withdrawal or
last follow-up visit schedule, patient status at the last visit,
date of death, and cause.
2.5. Statistical Analysis. The data were includedin a database
designed for this purpose for subsequent statistical analysis
using SPSS version 8.0.
We conducted a descriptive study of case characteristics
in a pooled analysis stratiﬁed according to HER-2 status.
The statistical association has been evaluated using the
chi-square test.
Quantitative variables were expressed as median and
range. Qualitative variables in absolute numbers and per-
centages. The survival data were analyzed according to
Kaplan-Meier method, and statistical signiﬁcance was tested
usinglog-ranktest.Wehaveperformedunivariateandmulti-
variate analysis to identify the role of overexpression and/or
ampliﬁcation of HER-2 and other factors as prognostic in-
dicators independently associated with DFS and OS.
3.Results
3.1. Positive Rate for c-erbB-2 and Correlation with Other
Clinicopathologic Factors. We analysed 120 cases of patients
underwent a completeradical resection forGC. Patient char-
acteristics are described in Table 2.
High expression of HER-2 protein by IHC 3+ was re-
corded in 8 cases, and overall expression (IHC 3+ or IHC 2+
and FISH positive) was detected in 7.5% of tumours. These
results are described in Table 3.
The incidence of c-erbB-2 positive was higher in women
with tumors located primarily antropyloric (although at
this point has not been detected statistical signiﬁcance) and
intestinal type. Also a greater proportion of patients detected
Table 2: Characteristics of the population studied.
Characteristics N
Median age (range) 56 (26–83)
Sex
Men 72
Women 48
Location
Antrum-pylorus 94
Gastrooesophageal and corpus 26
Type of gastric cancer
Intestinal 59
Diﬀuse/mixed 25/46
Nodes
Involved 98
Not involved 22
Table 3: HER-2 positivity.
IHC N FISH Concordance rate
+++ 8 8 ampliﬁcations 100%
++ 6 1 ampliﬁcations 16,6%
+ 70 0 %
with advanced tumors (pT3-4 and nodes involved) in the
subgroup of c-erbB-2 positive, as shown in Table 4.
3.2. Recurrence. After a median followup of 38 months
(range 15–67 months), in patients with HER-2 positive
66.6% recurrences were recorded (6 patients out of 9).
In these cases, the median time to recurrence was 9
months (range2–16months) comparedto19months (range
15–38 months) in the sample of patients with HER-2 neg-
ative, these diﬀerences being statistically signiﬁcant (P =
0.04).
Most of recurrences in HER-2 positive tumours were at
distance or combined (locoregional and distant), while in 14 Journal of Oncology
Table 4:HER-2 positiveandclinicopathologicalfactorscorrelation.
Clinicopathological factor NP
Sex
Male 3 0.019
Female 6
Histological grade
13
0.024 22
34
Histological type
Intestinal 8 0.038
Other 1
Location
Antral-pylorus 7 0.096
Oesophagogastric union and corpus 2
pT
pT3-pT4 7 0.034
Other 2
Metastatic nodes
Yes 7 0.031
No 2
of them only locoregional recurrence was detected in a con-
trol endoscopy although he was unﬁt to radical treatment.
Among patients who had recurrence of their tumour, it
was observed a statistically signiﬁcant diﬀerence in time to
recurrence according to the status of c-erbB-2.T h u s ,t h e
proportion of patients falling on the ﬁrst year (early relapse)
after diagnosis was higher in the HER-2 positive subgroup
(4 out of 6 patients) than in the negative one (66.6% versus
35.4%, P = 0.048).
3.3. Survival. Throughout the study period, we documented
two (22.3%) deaths due to tumor disease in the subgroup
of patients with c-erbB-2 positive. In this subgroup, there
were three people alive without evidence of disease. The rest
are undergoing palliative treatment. The median DFS for
the population c-erbB-2 positive was 15 months (range 2–
67 months) meanwhile for HER-2 negative was 27 months
(range 5–67 months) (P = 0.04). OS for HER-2 positive was
25 months (range 10–67 months) but with c-erbB-2 negative
was 47 months (range 29–67 months) (P = 0.039).
3.4. Univariate and Multivariate Analysis. Our univariate
analysis showed that the status of HER-2, sex, advanced
stage, and lymph node metastases were associated with poor
survival.
A multivariate Cox analysis only identiﬁed the status of
c-erbB-2 and the advanced stage as independent prognostic
factors (data not included).
4.Discussion
Our results have found that overexpression of the protein
HER-2byIHCconﬁrmedby ampliﬁcationoftheHER-2/neu
oncogene in cases of IHC ++, and are independent prognos-
ticfactorsinGCafterradicalresection,correlatedstatistically
signiﬁcant with early relapse (during a year after radical re-
section).
In this regard, we found that, among recurrences that
appear in this time period, 66.6% were in the HER-2 positive
subgroup compared to 35.4% detected in the c-erbB-2 nega-
tive (P = 0.048).
On the other hand, the univariate and multivariate anal-
yses also revealed that it is an independent factor that
correlates with worse survival. Both facts make our results
consistent with other published studies, prospective or
retrospective, suggesting thattheroutineassessment ofHER-
2/neu gene status should be a rule as it is a new prognostic
factor in GC.
This analysis detected also a statistically signiﬁcant dif-
ference in the median time to relapse according to HER-2
status subgroups. In this way we have obtained a shorter
time in patients with HER-2 positive (median 9 months)
compared to HER-2 negative sample (19 months). Similarly
there are diﬀerences in DFS or OS favoring those cases in
which overexpression and/or ampliﬁcation of c-erbB-2 was
not detected.
The study by Garc´ ıa et al., published in Ann of Surg
Oncol 2003, revealed that survival data were also favorable
to patients with HER-2 negative in a statistically signiﬁcant
way [19] as our study found.
We have also identiﬁed a statistically signiﬁcant associa-
tion between positivity for c-erbB-2 and female sex, undiﬀer-
entiated histological-grade tumours, intestinal histological
type, and presence of nodal metastases, showing an inter-
esting correlation with the presence of more than 6 nodes
metastatic (P = 0.052) although with a marginal signiﬁ-
cance.
On the contrary we have not detected signiﬁcant asso-
ciation with tumor location (antropyloric versus other loca-
tions) although most were located in antropylorus. In this
subject we diﬀer from other published studies which have
found a signiﬁcant correlation between positivity for c-
erbB-2 and the presence of tumours at the gastroesophageal
junction. Tanner et al. found that positive rates ranged from
24% to 12% for tumours located at the union or in other
areas of the stomach, respectively, [21]. The ToGA trial
revealed in the same way and got a range between 32% and
18% [22], respectively.
On the other hand, the concordance of protein overex-
pression and gene ampliﬁcation in GC has been controver-
sial. Recent studies have reported a high correlation between
both overexpression by IHC and ampliﬁcation by FISH.
The study by Yano et al. found an overall concordance
rate of 87% (58.8% for IHC ++ and 88% in cases of IHC
+++) [23]. And ToGA trial has also found high rates of
overall concordance (87%) [22].
Allthesestudieshavealsoshowedhighratesofagreement
between surgical specimens and biopsy specimens.Journal of Oncology 5
Against the others, our study has obtained lower con-
cordance rates, much diﬀerent than those described above.
The overall agreement we have obtained was 42.8%, which
means that only 9 cases of 21 positive by IHC (+ to +++)
showed oncogene ampliﬁcation by FISH. In the literature
it is thought to be due to cases with IHC 0/1+ which had
also gene ampliﬁcation by FISH. In ToGA trial this fact was
detected in almost the same percentage of IHC ++ and FISH
positive (23% and 26%, resp.) [22]. But we did not tested by
FISH those cases with IHC 0.
We have identiﬁed a concordance of 100% in cases with
tumours HER-2 with +++ by IHC so that all patients had
oncogeneampliﬁcation by FISH.Bycontrast, in casesofIHC
++ concordance was much lower, only found in 16.6% of
patients.
Thisﬁnding couldsupportthehypothesisthattheampli-
ﬁcation of the oncogene c-erbB-2 may not be the only mech-
anism involved in the overexpression of the protein in the
cell membrane in GC as suggested Kameda et al. [24]. On
the other hand, the work of Hollywood and Hurst [25]a l s o
suggested that overexpression of HER-2 may occur through
other molecular strategies such as transcriptional activation
by other genes. Another plausible explanation for this dis-
crepancy could be related to the fact of low HER-2 over-
expression in CG. This may involve a higher rate of false
positives to the nonspeciﬁc binding of primary antibody or
to the overvaluation of the union. In summary, our study
showed a low positivity rate of HER-2 but similar to other
series published in the literature, approaching to the initial
series published in the 1990s or even the latest Gr´ avalos and
Jimeno study [8]. This is probably due to the exclusion of
patients with metastases at diagnosis or even the extended
period of time considered for the inclusion of patients in our
project, with many diﬀerences in the protocols of ﬁxation
of the specimens that might contribute somewhat to the
appearance of false negatives.
5.Conclusions
The CG is the second leading cause of cancer death world-
wide because most are diagnosed in advanced stages with no
chance of cure. In this context, the systemic chemotherapy
remains the only treatment option, although with poor re-
sults, so new strategies are needed.
Every time there is more evidence of the importance of
HER-2 in these patients, with the positivity correlated with
poor survival outcomes due to the increased aggressiveness
of the disease.
There are experimental models showing that trastuzum-
ab (a monoclonal antibody that inhibits HER-2) suppresses
the growth of human GC. As a result of these promising data,
there have been conducted clinical trials of this antibody in
combination with platinum-based chemotherapy with good
results.
Our work contributes to emphasize the importance of
this biomarker in the context of a high-risk GC population
in the center of Spain. Although this is a retrospective study
with the limitations already described, the results provide us
with abetterunderstandingoftherelevanceofthisproteinas
aprognosticmarkerandindirectlyasatherapeutictargetand
encourage us to continue researching in molecular pathways
to improve the overall results and to optimize the clinical
application.
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